Les Kjosness, President & CEO, is pleased to announce Marapharm Ventures Inc. (the “Company”), has entered into an investor relations agreement (the “IR Agreement”) for a six month contract with Renmark Financial Communications Inc. (“Renmark) for investor relations services. The six month contract is to begin June 1, 2015 and the Company will pay to Renmark $7,000 CAD on a monthly basis. This contract may be terminated by either party at any time upon delivery of a 30 days’ notice. Renmark does not have any interest, directly or indirectly, in Marapharm Ventures Inc. or its securities, or any right or intent to acquire such an interest.
Renmark will assist in co-ordinating Marapharm’s existing investor relations activities with the retail brokerage community in North America. “We are pleased to have selected Renmark to help to reinforce our profile with retail investors, and to enhance the visibility of our projects within this extremely important segment of the investing community. Renmark’s standards and methodology fit the message we wish to communicate to the investing public,” noted Kjosness.
About Marapharm Ventures Inc.
Marapharm was formed to create a global entity by pursuing commercial ventures in the medical marijuana business. The Company’s original project is the construction of brand new facilities on 11 acres in British Columbia’s Okanagan Valley with expansion plans in place to meet strategic advantages for growth and market penetration. Marapharm is currently in the process of its application for an MMPR license. In May 2015, we announced the purchase of 5.9 acres in the Apex Industrial Park, located in North Las Vegas, Nevada. The Company has a provisional grow licence in place and will build a 70,000 square foot medical marijuana facility. Building plans are completed and are in the final rounds for permitting. Construction will start within 60 days. In addition to the Las Vegas acquisition, Marapharm has entered into an LOI (letter of intent) with the same business corporation for a 90-day exclusive negotiation rights and the right of first refusal for two additional Nevada Medical Marijuana licences, one Medical and recreational Marijuana grow operation in Colorado, one grow operation and a medical dispensary licence in Washington State and one medical dispensary licence in California.
On behalf of the Board
President & Director
For further information please visit the Company`s website at www.marapharm.com
The CSE has neither approved nor disapproved the accuracy of this news release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Companies’ documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward – looking statements, which speak only as of the date of this news release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward – looking statements, whether as a result of new information, future events or otherwise.